NEWS & EVENTS

Latest News

The Importance of an Experienced SME Regulatory Consultant for Non-EU Pharmaceutical Companies

For non-EU small and medium-sized pharmaceutical enterprises, establishing a foothold in the European market is essential. Leveraging the European Medicines Agency’s (EMA) Small and Medium-Sized Enterprise (SME) status can offer significant regulatory and financial benefits. However, non-EU companies must navigate the process through an EU-registered third party, ideally a seasoned SME regulatory consultancy. Advantages of […]

Weiterlesen →

Critical Steps in Effective CMC Management for Rare Disease Products

The process of meeting Chemistry, Manufacturing, and Control (CMC) requirements poses significant challenges for drug developers, particularly in the rare disease sector. Non-EU sponsors aiming to conduct clinical trials in Europe encounter additional complexities, as the regulatory expectations of the European Medicines Agency (EMA) often differ from those of other regulatory agencies, such as the […]

Weiterlesen →

Umfassender Leitfaden für die Umstellung auf CTIS

Um klinische Prüfungen, die zuvor im Rahmen der EU-Richtlinie über klinische Prüfungen genehmigt wurden, erfolgreich auf das EU-Informationssystem für klinische Prüfungen (CTIS) umzustellen, müssen die Sponsoren mehrere wesentliche Vorbereitungsmaßnahmen ergreifen. Diese Vorbereitungsschritte können umfangreich sein und werden oft missverstanden, was die Notwendigkeit einer gründlichen Vorbereitung unterstreicht. Erste Vorbereitungen Beginnen Sie damit, sicherzustellen, dass Sie über eine Erklärung [...]

Weiterlesen →

Allowing Sufficient Time for Legal Representative Evaluation in Compliance with the Clinical Trials Regulation

The implementation of the Clinical Trials Regulation (CTR) has introduced additional complexities for non-EU sponsors, particularly concerning the obligations of the legal representative. Non-EU sponsors are mandated to appoint an EU-based legal representative to ensure compliance with CTR standards. While the requirement for a legal representative is not new, the CTR explicitly tasks them with […]

Weiterlesen →

Understanding SME Status: A Catalyst for Innovation

The European Medicines Agency (EMA) offers a pivotal advantage to Small and Medium-Sized Enterprises (SMEs) engaged in the development of medicinal products for both human and veterinary applications. The designation of SME Status serves as a strategic initiative designed to foster innovation and encourage the creation of novel therapies. Instituted through the SME Regulation of […]

Weiterlesen →

The Significance of Data Transparency: Posting Trial Results on EudraCT and CTIS

Within the context of the Clinical Trial Regulation, there is an essential emphasis on transparency. It is imperative that sponsors recognize their obligations concerning data transparency for trials executed in the EU, specifically those concluding under the Clinical Trial Directive (CTD). Sponsors are obligated to ensure that results from such studies are submitted to the […]

Weiterlesen →

Events

43rd Annual J.P.Morgan Healthcare Conference

JANUARY 13-16, 2025 | SAN FRANCISCO, CALIFORNIA

This premier conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.

https://www.jpmorgan.com/about-us/events-conferences/health-care-conference